• Plenary
  • Workshop
  • Side Meeting
  • 07:30

    Registration and refreshments

    Time: 07:30

    Summit booths will be open during this time.

  • 09:30

    Opening session and Partner introductions

    Time: 09:30

    Golden Hall

    The official opening ceremony from the Partners, hosts and officials of the World Hepatitis Summit 2017.

  • 10:30

    Making elimination a reality

    Time: 10:30

    Golden Hall

    Session Lead: Gottfried Hirnschall

    Speakers: Raquel Peck

    This session will bring together a group of visionaries from all walks of life who champion the cause of elimination to participate in a dialogue around achieving the common goal of elimination.

    Presentations:

    • Making elimination a reality: overview.

      Speaker: Dr. Gottfried Hirnschall, World Health Organization

    • NOhep Visionaries.

      Speakers: Raquel Peck, World Hepatitis Alliance

    • High level panel.
  • 12:30

    Lunch

    Time: 12:30

    Summit booths will be open during this time.

  • 13:30

    Strategic direction 1: strategic information for focused action

    Time: 13:30

    Golden Hall

    The Summit’s agenda takes the Global Health Sector Strategy on Viral Hepatitis (GHSS) - and its 5 strategic directions - as its framework. In this plenary session, strategic direction 1 looks at advocacy, political commitment and national planning.

    Chairs: Dr. Leolin Katsidzira, University of Zimbabwe College of Health Sciences and Tatjana Reic, European Liver Patients’ Association

    Presentations:

    • Global viral hepatitis situation and response.

      Dr. Marc Bulterys, World Health Organization

    • WHO country profiles report.

      Prof. Sharon Hutchinson, Glasgow Caledonian University, UK

    • The power of people: integrating civil society in the global hepatitis response.

      Charles Gore, World Hepatitis Alliance

    • The role of liver societies in the global viral hepatitis response.

      Anna Lok, American Association for the Study of Liver Diseases

    • Country level experience of using strategic information to inform their national hepatitis response. 
      Zimbabwe - Rapid assessments: Dr. Leolin Katsidzira, University of Zimbabwe College of Health Sciences
      Vietnam - Hepatitis surveillance: Dr. Tran Dai Quang, Ministry of Health, Viet Nam
    • Q&A session.

    Session objectives:

    To highlight

    • The role and importance of strategic information in planning and monitoring national responses.

    • The priority actions for countries and role of WHO in supporting countries.

    • The latest data on the global viral hepatitis situation and response.

    • Progress made in integrating civil society in the global viral hepatitis response and on global awareness activities.

    • Country examples demonstrating the important role of strategic information for focused action.


  • 15:00

    Break

    Time: 15:00

    Summit booths will be open during this time.

  • 15:30

    The critical role of strategic information: HCV elimination in Georgia

    Time: 15:30

    Ballroom 1

    Chairs: Dr. Francisco Averhoff, US Centers for Disease Control and Prevention and Dr. Helen Harris, Public Health England

    Presentations:

    • The birth of The HCV elimination in Georgia: the focus on strategic information.
    • Assessing the burden of disease: the planning, conduct and use of a National Seroprevalence Survey.
    • Dr. Amiran Gamkrelidze, National Center for Disease Control and Public Health of Georgia
    • Monitoring the care cascade: developing a robust screening and treatment information system.
    • Dr. Lia Gvinjilia, CDC Foundation
    • The critical role of research in HCV elimination.
    • Dr. Tinatin Kuchuloria, CDC Foundation
    • Modelling the epidemic to guide interventions.
    • Prof. Peter Vickerman, University of Bristol, UK
    • Q & A session.

    Session objectives:

    • Learn the importance of a well conducted population serosurvey to guide development of an evidence-based national strategy/plan.
    • Understand the importance of a robust strategic information system to guide and monitor an elimination program.
    • Learn the key role of partnerships in developing a world class information system.
  • 15:30

    Developing a national plan on viral hepatitis

    Time: 15:30

    Ballroom 2

    Session Lead: Angelina Sijaona

    Chair: Joumana Hermez, World Health Organization and Seyed Moayed Alavian, Iran Hepatitis Network

    Presentations:

    • Developing a national plan: country examples.
      Uzbekistan: Dr. Erkin Musabaev, Ministry of Health, Uzbekistan
      Tanzania: Angelina Sijaona, Ministry of Health, Community Development, Gender, Elderly and Children, Tanzania
      Greece: Prof. George Papatheidoridis, Athens Medical School and Laiko Hospital of Athens, Greece
    • The contents and the process of developing national plans.
    • Joumana Hermez, World Health Organization
    • Streamlining national plans with the global and regional strategies.
    • Dr. Hande Harmanci, World Health Organization
    • Q & A session.

    Session objectives:

    • Learn to differentiate between national strategies and plans.
    • Identify the best processes to create national plans.
    • Use a checklist to align national plans with the Global Health Sector Strategy on Viral Hepatitis.
    • Critically appraise a national plan for comprehensiveness.
  • 15:30

    How to develop an investment case?

    Time: 15:30

    Golden Hall

    Chair: Dr. Jeremy Lauer, World Health Organization and Dr. Mehlika Toy, Stanford University, USA

    Presentations:

    • Economic analysis for HCV treatment in India: first building block of an investment case.
      Dr. Rakesh Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences
    • The hepatitis C economic analysis calculator: an interactive tool at the service of countries.
    • Dr. Jagpreet Chhatwal, Harvard Medical School and Massachusetts General Hospital
    • Breakout interactive session with the calculator in the 28 focus countries.
    • From cost effectiveness of treatment towards a broad investment case.
    • Dr. Yvan Hutin, World Health Organization

    Session objectives:

    • Describe the role of an investment case/economic analysis in the national planning process.
    • Differentiate a cost effectiveness analysis from health care perspective from a broader cost-benefit analysis/investment case.
    • Identify the elements needed for a national investment case/economic analysis in practice.
  • 15:30

    How to develop successful awareness raising campaigns?  Harnessing the learning from civil society and other global initiatives

    Time: 15:30

    Ballroom 3

    Session Lead: Sema Mandal , Achim Kautz

    Chairs: Achim Kautz, Leberhilfe Projekt gUG and Dr. Sema Mandal, Public Health England

    Presentations:

    • Beyond hepatitis – experiences to mobilize society.
    • Dr. Renata Schiavo, ‎Strategic Communication Resources, and Health Equity Initiative, and Columbia University
    • The power of data to drive advocacy.
    • Tara Farrell, World Hepatitis Alliance
    • Country case studies.
      Bangladesh: Dr. Mohammad Ali, National Liver Foundation of Bangladesh
      United States: Dr. Cynthia Jorgensen, US Centers for Disease Control and Prevention
    • Q & A session.

    Session objectives:

    • Lessons learnt from global awareness strategies in other fields.
    • Lessons learnt from major hepatitis awareness strategies.
    • Identify key data needed to structure awareness strategies.
    • How a global awareness strategy can be used - based on local data - at a local level?
  • 17:00

    Close of day 1

    Time: 17:00

  • 17:30

    Speeding access to innovative hepatitis C products: Unitaid’s key role

    Time: 17:30

    Chagal

    This evening side meeting presents Unitaid’s investment and operating model in the context of the emerging global response to hepatitis C. It will share the results of Unitaid-funded projects related to hepatitis C. It will also explore opportunities for potential future investments. 

    Presentations:

    • Opening remarks – Unitaid’s model and its relevance for Hepatitis C.
    • Where are we today?
    • Developing a simplified mode of care for HCV.
      Anne Loarec, Médicins Sans Frontère
    • Creating demand and innovative solutions for access to HCV treatment.
      Khalil Elouardighi, Coalition Plus
    • Facilitating access to HCV treatment through voluntary licensing
      Greg Perry, Medicines Patent Pool
    • Facilitating diagnostic solutions
      Francesco Marinucci, FIND
    • Putting the pieces together to maximise benefits.
      Dr. Marc Bulterys, World Health Organization
    • Moderated discussion.
  • 17:30

    Policy as a tool for HepC Elimination

    Time: 17:30

    Matisse

    Hepatitis C virus (HCV) infection is considered a major Public Health threat in Europe.

    Hepatitis C virus (HCV) infection is considered a major Public Health threat in Europe. Hepatitis C is a chronic infectious disease with great impact on patients’ morbidity and mortality, with high risk of progression to cirrhosis and liver cancer. In Europe, it is estimated that only 25% of patients with hepatitis C are diagnosed (~14 million people); each year there are 27,000-29,000 newly diagnosed HCV cases in the EU/EEA. Evidence shows that, for some European countries, annual deaths from hepatitis c have quadrupled over the past 20 years. New treatments were recently discovered that cures hepatitis C in up to 97% of cases. This, alongside the devastating effects that the disease can have, means that the paradigm at the community level of hepatitis c treatment should now be elimination.

    Presentations:

    • From policy to action.
      Charles Gore, World Hepatitis Alliance
    • What matters to patients - HepCore.
      Prof. Jeffrey Lazarus, University of Copenhagen
    • Empowering advocates.
      Achim Kautz, Leberhilfe Projekt gUG
    • Modelling for policy change.
      Dr. Homie A. Razavi, Center for Disease Analysis Foundation
    • Brazil strategy and response to HCV.
      Evaldo Stanislau Affonso de Araújo, Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo
    • Let's End HepC Dashboard - assessing and comparing different Countries policies in real-time towards the elimination of HCV until 2030.
      Ricardo Baptista Leite, Member of the Portuguese Parliament and Católica University of Portugal
  • 07:30

    End of viral hepatitis? Not without tackling hepatitis E!

    Time: 07:30

    Chagal

    Session Lead: Iza Ciglenecki

    This early morning side meeting will look at this neglected form of the hepatitis virus and the limited strategies to control it. With no efficacious treatment available for acute fulminant hepatitis E and a limited impact from improvements in water and sanitation in displaced populations, this meeting will examine what can be done to limit the burden worldwide. 

    Presentations:

    • Introduction: Hepatitis E in humanitarian settings.
      Iza Ciglenecki,‎ Médecins Sans Frontières
    • Hepatitis E in developing countries: an old disease?
      Dr. Rakesh Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences
    • Hepatitis E in developed countries: a new disease?
      Dr. Harry Dalton, Royal Cornwall Hospitals NHS Trust
    • Hepatitis E vaccine: a new control tool?
      Dr. James Shih, Innovax
    • Round table discussion.
      Moderator: Dr. Harry Dalton, Royal Cornwall Hospitals NHS Trust
      with Dr Rajendra Pant, Dr Rakesh Aggarwall, Dr Philippa Easterbrook

  • 08:00

    Registration and refreshments

    Time: 08:00

  • 08:00

    Liver societies' role towards viral hepatitis elimination

    Time: 08:00

    Matisse

    Topics to be discussed:

    • Prevention of mother to child transmission of HBV and strategies to increase HBV vaccine coverage (in particular birth dose coverage) and antiviral therapy for highly viremic HBsAg+ mothers.
    • Improving diagnosis of persons chronically infected with HBV or HCV.
    • Improving linkage to care of persons diagnosed to have chronic HBV or HCV, in particular vulnerable populations and persons living in rural areas.
    • Improving access to antiviral treatment of persons with chronic HBV or HCV.
  • 09:15

    Strategic direction 2: interventions for impact and strategic direction 3: delivering for equity

    Time: 09:15

    Golden Hall

    The second day of the Summit is dedicated to strategic directions 2 and 3, which cover the issues of "interventions for impact" and "delivering for equity".

    Chairs: Dr. Florence Zeh Kakanou, Ministry of Public Health, Cameroon and Dr. Saeed Hamid, The Aga Khan University, Pakistan

    Presentations:

    • 5 core interventions to reach HBV and HCV elimination.
      Dr. Hande Harmanci, World Health Organization
    • Scaling-up of treatment services in Brazil.
      Dr. Adele Benzaken, Ministry of Health, Brazil
    • Hepatitis B services – challenges and opportunities.
      Dr. Chukwuma Anyaike, Federal Ministry of Health, Nigeria
    • Continuum of interventions to prevent HBV infection at birth and in the first years of life
    • Dr. John Ward, US Centers for Disease Control and Prevention
    • Hepatitis C prevention and treatment for PWID.
      Prof. Gregory Dore, Kirby Institute, UNSW Sydney and St Vincent’s Hospital, Sydney
    • Hepatitis services for indigenous people.
      Luana Silveira de Faria, Ministry of Health, Brazil
    • Q & A session.

    Session objectives:

    • Learn areas of innovation and neglected issues.
    • Hear about the core issues for elimination and equitable access.
    • Gain an overview of the main advocacy areas and gaps.
  • 10:45

    Break

    Time: 10:45

    Summit booths will be open during this time.

  • 11:15

    Access to hepatitis medicines

    Time: 11:15

    Golden Hall

    This panel session examines the key barriers and current strategies to scale up access to hepatitis treatment.

    Chair: Dr. Jackson Amone, Ministry of Health, Uganda and Ricardo Baptista Leite, Member of the Portuguese Parliament and Católica University of Portugal

    Presentations:

    • Generic DAAs; where they are and for how much.
    • Giten Khwairakpam, amfAR
    • What price for what drug: is there a science to it?
    • Dr. Andrew Hill, Liverpool University, UK
    • Options for treatment access in countries with and without access to generics and role of different actors.
    • Dr. Yvan Hutin, World Health Organization

    Objectives:

    • To review different approaches to overcoming access barriers and the progress made.

     

  • 12:00

    Options for countries without access to generic hepatitis medicines

    Time: 12:00

    Ballroom 1

    Chairs: Ellen ‘t Hoen, University of Groningen, Netherlands and Dr. Massimo Ghidinelli, World Health Organization

    Presentations:

    • Introduction to Intellectual Property.
      Ellen ‘t Hoen, University of Groningen, Netherlands
    • Patent opposition.
    • Olivier Maguet, Médecins du Monde
    • Malaysian strategy for access to HCV DAAs: road to compulsory licensing.
    • Shangeetha Thirumayni, Malaysian AIDs Council
    • How the interplay among scientific societies, medicines agency, and patients associations favoured drug price negotiation and allowed universal treatment of HCV: the Italian experience.
      Prof. Edoardo G. Giannini, University of Genoa, Italy
    • PAHO Strategic Fund - pooled procurement to improve access to high cost hepatitis medicines in commercial markets.
    • Juliana Vallini, Pan American Health Organization
    • Q & A session.
  • 12:00

    Options for countries with access to generic hepatitis medicines

    Time: 12:00

    Ballroom 2

    Session Lead: Jean Damascène Makuza

    Chair: Dr. Jean Damascène Makuza, Rwanda Biomedical Center and Tracy Swan, Médecins Sans Frontières

    Presentations:

    • Country example: Rwanda.
      Dr. Jean Damascène Makuza, Rwanda Biomedical Center
    • The impact of generics in scaling up treatment.
    • Dr. Saeed Hamid, The Aga Khan University, Pakistan
    • Voluntary licensing.
      Greg Perry, Medicines Patent Pool
    • Basics of access to medicines for hepatitis programme managers.
    • Madisyn Lu, Clinton Health Access Initiative
    • Q & A session.
  • 12:00

    Advocacy for access to hepatitis treatment

    Time: 12:00

    Golden Hall

    Chairs: Jennifer Johnston, CEVHAP and Dr. Bobby John, Global Health Advocates, India

    Presentations:

    • Introduction and vision.
      Othoman Mellouk, International Treatment Preparedness Coalition
    • Advocacy for access for the most vulnerable populations.
    • Luís Mendão, GAT - Treatment Activist Group
    • Brazilian experience on patent opposition.
    • Felipe de Carvalho, Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples (GTPI/Rebrip)
    • DNDi strategy on access to hepatitis C medicines.
      Francisco Viegas, Drugs for Neglected Diseases Initiative
    • Role of the civil society: case study in a country with access to generics.
    • Rajkumar Nalinikanta, CoNE Manipur
    • Q & A session.
  • 12:00

    Measuring access to medicines and reporting mechanisms

    Time: 12:00

    Ballroom 3

    Chairs: Dr. Jose Gerard B. Belimac, Department of Health, Philippines and Dr. B. B. Rewari, World Health Organization

    Presentations:

    • Patient-centered monitoring and case surveillance: an HIV example.
      Frank Lule, World Hepatitis Organization
    • Country experiences.
    • Implementation of the Federal Registry for Viral Hepatitis B, C and D in Russia: Dr. Vladimir Chulanov, Central Research Institute of Epidemiology, Moscow, Russia  Mongolia: Dr. Chinburen Jigjidsuren, Ministry of Health, Mongolia
    • Indicators to measure and report treatment coverage.
    • Yvan Hutin, World Health Organization
    • Q & A session.
  • 12:00

    Service delivery - models for testing and treatment

    Time: 12:00

    Chagal

    Session Lead: David Goldberg

    Chair: Dr. David Goldberg, Health Protection Scotland

    • Need for task shifting and decentralization in treatment delivery to fight against hepatitis B: a situation analysis of Madagascar.
    • Lessons Learned from HIV Screening: Routine HCV Screening and linkage to care in an Urban Emergency Department in Chicago, IL.
    • Population Based Screening For HBV- Critical Step To Improve The Clinical Outcomes Of HCC Patients In Africa:Survey Study From African Practitioners.
    • The hepatitis virus screening program in Thailand: an eight-year experience of population study.
    • O "julho amarelo" e a "frente parlamentar mista de combate às hepatites virais" são intervenções de impacto sobre as hepatites virais.
  • 13:00

    Lunch

    Time: 13:00

    Summit booths will be open during this time.

  • 13:00

    Service delivery for viral hepatitis 1: priority populations

    Time: 13:00

    Matisse

    WHO is currently preparing guidance on good practice principles for simplified service delivery and for provision of specific care needs in priority populations.

    Worldwide, only a small proportion of people with chronic HBV or HCV infection in low and middle income countries are diagnosed and then access treatment. Achieving the global targets towards elimination will require adoption of simplified and accessible service delivery approaches to promote access to testing, prevention and treatment of hepatitis B and C infection.

    The objective of the two side sessions on service delivery is to present a framework for the proposed guidance with an interactive discussion on framework and content from wide range of Summit participants. 

    The first one hour session will cover core guidance and good practice principles for priority populations – PWID, people in prisons, MSMs, migrants and indigenous populations, pregnant women, and adolescents and children.

    Presentations:

    • Overview of proposed WHO service delivery good practice principles for viral hepatitis.
      Philippa Easterbook, WHO
    • PWID.
    • People in prisons.
    • Indigenous populations.
    • Adolescents and children.
    • General discussion.
  • 13:00

    Modelling and cost effectiveness for global scale up

    Time: 13:00

    Chagal

    Chairs: Dr. Benjamin Cowie, Doherty Institute, and Liudmyla Maistat, Medicines Patent Pool

    • Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
    • Modelling the Scale-up of Screening, Treatment, and Prevention Interventions to Achieve WHO Elimination Targets for Hepatitis C Virus in Pakistan.
    • HCV treatment and prevention: What is the impact of current and scaled-up treatment rates in selected sites in Europe?
    • Modelling the global elimination of hepatitis C.
    • The cost-effectiveness of general population based HCV screening in India.
  • 14:00

    Testing interventions

    Time: 14:00

    Ballroom 1

    Chairs: Dr. Maria Cassia Mendes-Correa, Sao Paulo University, Brazil and Dr. Francesco Negro Geneva University Hospital, Switzerland

    Presentations:

    • Introduction including a brief overview of WHO testing guidelines and implementation.
    • Prof. Philippa Easterbrook, World Health Organization
    • Diagnostics: present and future innovations.
    • Dr. Saleem Kamili, US Centers for Disease Control and Prevention
    • Are HBV community-based screening campaigns feasible and acceptable: the PROLIFICA experience.
    • Dr. Maud Lemoine, Imperial College London, UK
    • Scaling-up a national screening programme for hepatitis C.
    • Dr. Radi Hammad, Ministry of Health, Egypt
    • Q & A session.

    Session objectives:

    • Review the scientific, logistical, ethical and political process leading to the implementation of state-of-the-art testing for viral hepatitis.
    • Discuss the feasibility and validity of diagnostic algorithm simplifications.
    • Define what testing strategies should be applied in different settings.
    • Discuss the preliminary results of testing strategies in selected areas.
  • 14:00

    Treatment interventions

    Time: 14:00

    Ballroom 2

    Chair: Prof. Rosmawati Mohamed, University Malaya Medical Centre, and Dr. Saeed Hamid, The Aga Khan University, Pakistan

    Presentations:

    • Lessons learned from implementing a successful treatment programme.
    • Dr. Chinburen Jigjidsuren, Ministry of Health, Mongolia
    • Hepatitis interventions as part of prisons health programmes.
    • Dr. Benjamin Cowie, Doherty Institute
    • Treatment in the private vs public sector.
    • Pakistan: Dr. Saeed Hamid, The Aga Khan University, Pakistan
      Argentina: Jesse Maid, Ministry of Health, Argentina
    • Q & A session.

    Session objectives:

    • Highlight the impact various factors have had in significantly up scaling treatment, particularly in the LMIC.
    • Identify what treatment intervention strategy would work best in their own environments.
  • 14:00

    Prevention interventions

    Time: 14:00

    Ballroom 3

    Session Lead: Mark Jacobs , Amr Kandeel

    Chair: Dr. Amr Kandeel, Ministry of Health, Egypt and Dr. Mark Jacobs, World Health Organization

    Panel:

    • Viral hepatitis prevention efforts in Egypt – successes and challenges.
    • Dr. Amr Kandeel, Ministry of Health, Egypt
    • WHO Injection Safety Project.
    • Dr. Arshad Altaf, World Health Organization
    • Implementing injection safety at the country level: challenges and opportunities.
    • Dr. Huma Qureshi, Pakistan Health Research Council
    • Towards zero transmission of HBV from mother to child: new data and the SHIELD project.
    • Dr. Jinlin Hou, Nanfang Hospital, China
    • HCV prevention among people who use drugs: evidence and ways forward.
      Dr. Niklas Luhmann, Médecins du Monde
    • Blood safety and hepatitis.
    • Dr. Marcelo Addas-Carvalho, Blood Center of Campinas/UNICAMP
    • Q & A session.

    Session objectives:

    • Discuss different core areas of viral hepatitis prevention.
    • Hear country examples of good practice for health facility injection safety, vertical transmission and blood product safety.
  • 14:00

    Delivering equitable services

    Time: 14:00

    Golden Hall

    Chairs: Prof. Chris Cunningham, Massey University, New Zealand and Dr. Antons Mozalevskis, World Health Organization

    Presentations:

    • Welcome and introduction to workshop.
    • Prof. Chris Cunningham, Massey University, New Zealand
    • Introduction to PROGRESS.
      Dr. Janet Hatcher Roberts, University of Ottawa, Canada
    • Worked Scenario.
    • Participants apply PROGRESS to a scenario.
    • Feedback from participants.

    Session objectives:

    • Understand the concept of an "equity lens".
    • Apply an equity framework to policy/service settings relevant to viral hepatitis.
  • 14:00

    Delivering high quality hepatitis services

    Time: 14:00

    Ballroom 4

    Session Lead: Liudmyla Maistat

    Chair: Liudmyla Maistat, Medicines Patent Pool and Prof. Njoya Oudou, Research Laboratory on Viral Hepatitis and Health Communication

    Presentations:

    • Australia hepatitis service delivery model.
    • Prof. Margaret Hellard, Burnet Institute, The Alfred Hospital and Monash University, Australia
    • HCV testing, treatment and care of people who inject drugs
    • Abigael Lukhwaro, Médecins du Monde
      Sergii Filippovych, Alliance for Public Health
      Prof. David Goldberg, Health Protection Scotland
    • Integrating hepatitis into public health services.
      Prof. Olga Golubovska, Bogomolets National Medical University and Ministry of Health, Ukraine
    • HBV services and indigenous people.
    • Dr. Brian McMahon, Alaska Native Tribal Health Consortium
    • Q & A session.

    Session objectives:

    • Review examples of service delivery models for different population groups.
    • Discuss gaps in HBV vaccination, HBV and HCV testing, diagnosis, treatment and care cascade for key populations in different settings and possible solutions to filling in the gaps.
    • Assess the role of case management; peer-to-peer support in community-based or community oriented service delivery.
  • 14:00

    Epidemiology and risk factors for viral hepatitis - a global perspective

    Time: 14:00

    Chagal

    Chairs: Dr. Stefan Wiktor, University of Washington, Seattle and Manal El-Sayed, Ain Shams University, Cairo

    • Prevalence of Hepatitis B and C among female sex workers and its clients in Ukraine.
    • Hepatitis B: changes in epidemiological and molecular features of Afro-Brazilian communities, central Brazil.
    • The Efficacy of Combined Sofosbuvir and Daclatasvir in Treating Hepatitis C Patients – A Preliminary Report.
    • Hepatitis B prevalence and risk factors in Georgia: a nationwide survey.
    • Knowledge and awareness amongst illiterate females aged 18-65 years on causes of Hepatitis and Liver disease in urban slums in India.
    • Relevance of implementation of institutional policy to protect health care workers exposed to Hepatitis B virus (HBV) or Hepatitis C virus (HCV) –contaminated blood or body fluids: experience from a tertiary care liver centre in India.
  • 15:30

    Break

    Time: 15:30

    Summit booths will be open during this time.

  • 16:00

    Parallel workshops

    Time: 16:00

    Golden Hall and Ballrooms 1-4

    Parallel workshops from 14:00 repeated. Choose from:

    • Testing interventions - Ballroom 1
    • Treatment interventions - Ballroom 2
    • Prevention interventions - Ballroom 3
    • Delivering equitable services - Golden Hall
    • Delivering high quality hepatitis services - Ballroom 4
  • 16:00

    National and population-specific experience with national scale up

    Time: 16:00

    Chagal

    Chair: Laura Ann Thomas, Doherty Institute and Dr. Stefan Wiktor, University of Washington, Seattle

    • Development of the South Africa Action Plan for Viral Hepatitis.
    • Potential barriers to implementing timely birth dose vaccination of hepatitis B in sub-Saharan Africa: A comparative anthropological study in Madagascar and Senegal.
    • Eliminating Hepatitis C in Iranian Prisoners as Part of the Nation-Wide Hepatitis C Elimination Program – A Pilot Study.
    • An Investigation of Real-World Community Effectiveness in HCV Treatment for Policy-making Toward Elimination of HCV by 2030 in Taiwan, China.
    • Hepatitis Prevention, Control, and Elimination Program in Mongolia: A Global Model for Eliminating Major Cancer-Causing Infectious Diseases.
    • High SVR rates using parallel imported generic DAAs in 1160 patients with Hepatitis C.
    • Progress towards elimination: Factors associated with a ten-fold increase in people who inject drugs initiating direct acting antiviral therapies in Australia in 2016.
  • 17:30

    Close of day 2

    Time: 17:30

  • 18:00

    Hepatitis in children

    Time: 18:00

    Chagal

    Session Lead: Manal El-Sayed

    This evening side meeting looks at hepatitis in children and adolescence. The session will explore some of the recent advances in pediatrics as well as the unique challenges that still need to be overcome within this area.

    Presentations:

    • Global overview of hepatitis in children: WHO perspective.
      Prof. Philippa Easterbook, World Health Organization
    • Towards elimination of HBV in Children: prevention perspective.
    • Towards elimination of HCV in children: clinical and treatment perspective.
      Prof. Manal El-Sayed, Ain Shams University, Egypt
    • Panel discussion.
      Prof Saeed Hamid (Pakistan), Prof Funmi Lesi (Nigeria), Prof Gilda Porta (Brazil)
  • 18:00

    Addressing the neglected burden of hepatitis D

    Time: 18:00

    Matisse

    Session Lead: Adele Benzaken

    Speakers: César Cabezas

    This evening side meeting will examine the challenges around the hepatitis D epidemic and what is being done to tackle it. Case studies will include Brazil’s response to the disease in the north of the country as well as highlights from the World Indigenous Peoples Conference on Viral Hepatitis (August 2017, Alaska).

    Presentations:

    Moderator: Carlos Varaldo, NGO Aliança Independente dos Grupos de Apoio

    • Plan of action of viral hepatitis in the Amazon region.
      Dr. Adele Benzaken, Ministry of Health, Brazil
    • Peru’s response to hepatitis D.
      Dr. Cezar Cabezas, Instituto Nacional de Salud, Peru
    • Highlights from the World Indigenous Peoples Conference.
      Dr. Wornei Braga, University of Amazonas, Brazil

  • 07:30

    Service delivery for viral hepatitis 2: good practice principles in health delivery

    Time: 07:30

    Chagal

    WHO is currently preparing guidance on good practice principles for simplified service delivery and for provision of specific care needs in priority populations.

    The second session will cover core good practice principles in service delivery - simplified and standardized algorithms across the continuum of care; strategies to strengthen uptake of testing, linkage to care and adherence; Integrated testing, care and treatment; decentralisation of care where appropriate to promote access; and community engagement with peer support.

    Presentations:

    • Overview of proposed WHO service delivery good practice principles for viral hepatitis care.
      Philippa Easterbook, WHO
    • Integrated testing and integrated diagnostic platforms with HIV and TB.
    • Integrated and differentiated care.
    • Decentralisation and task shifting.
    • Communnity engagement.
    • General discussion.
  • 08:00

    Registration and refreshments

    Time: 08:00

  • 09:00

    Strategic direction 4: financing for sustainability

    Time: 09:00

    Golden Hall

    The first of two plenary sessions on strategic direction 4, which addresses the sustainable financing of hepatitis responses within a whole health systems approach.

    Chairs: Dr. Amanda Kgomotso Vilakazi Nhlapo, National Department of Health, South Africa and Dr. John Ward, US Centers for Disease Control and Prevention

    Presentations:

    • A strategic approach to financing hepatitis.
      Charles Gore, World Hepatitis Alliance
    • Costing, delivery and financing for hepatitis – the linkages.
      Dr. Jeremy Lauer, World Health Organization
    • Panel discussion: financing for hepatitis within a health systems approach.
      Moderator: Dr. Eduardo González Pier, Center for Global Development
      Dr. David Wilson, World Bank
      Dr. Jean Damascene Makuza, Rwanda Biomedical Center
      Dr. Jeremy Lauer, World Health Organization
      Dr. Homie Razavi, Center for Disease Analysis Foundation

      Dr. Cielo Yaneth Ríos-Hincapié, Ministry of Health and Social Protection, Colombia

    Session objective:

    • Discover how to approach hepatitis costing, budgeting and financing in a structured way.
    • Understand how the financing system must match the service delivery model and where there are opportunities for integration.
    • Learn how countries can best approach sustainable financing for hepatitis.
  • 10:30

    Break

    Time: 10:30

    Summit booths will be open during this time.

  • 11:00

    Different financing mechanisms for viral hepatitis programmes

    Time: 11:00

    Golden Hall

    This session examines potential hepatitis financing mechanisms that will be required for countries to launch, accelerate and sustain public health responses to viral hepatitis.

    Chairs: Dr Adele Benzaken, Ministry of Health, Brazil and Dr. Philippe Duneton, Unitaid

    Presentations:

    • From economic analysis to financial dialogue.
      Dr. Homie Razavi, Center for Disease Analysis Foundation
    • A new Fund for Elimination of Viral Hepatitis: EndHEP2030.
      Wangsheng Li, Zeshan Foundation
    • Getting started with funding: catalytic initiatives.
      Taryn Barker, Clinton Health Access Initiative
    • Engaging Ministries of Finance.
      Eduardo González-Pier, Center for Global Development
    • Domestic funding.
    • Jeremy Lauer, World Health Organization, in conversation with Dr. Chinburen Jigjidsuren, Ministry of Health, Mongolia
    • Q & A session.

    Session objectives:

    • Understand the global investment case and its use in attracting donors.
    • Learn how to ensure the support of Ministries of Finance.
    • Understand how the public and private sector can be combined.
    • Discover how 3 countries have approached hepatitis financing.

  • 12:30

    Lunch

    Time: 12:30

    Summit booths will be open during this time.

  • 12:30

    Public private partnership to eliminate hepatitis and the role of the civil society

    Time: 12:30

    Chagal

    Session Lead: Wangsheng Li , Homie Razavi

    A lunchtime roundtable organized by GPRO and ZeShan Foundation in partnership with EndHEP2030.

    Please note that this session is invite only.

    Achieving the 2030 hepatitis elimination goals will require all stakeholders to work together. The objective of this session is to provide a platform for the participants to discuss their needs and what they can offer. All participants will receive a questionnaire prior to the meeting. We will review the responses according to the following categories: Public health organizations (national and international), donors, philanthropic foundations, industries, civil society, and government entities. We will then use a facilitated discussion (with the audience) to explore the types of partnerships that are needed to achieve the elimination target. This session is recommended for all who want to contribute to helping shape future partnerships. Attendance is by invitation only and all attendees are required to RSVP.

    Presentations:

    Chairs: Dr. Homie Razavi, Center for Disease Analysis Foundation and Wangsheng Li, ZeShan Foundation

    • How private and corporate philanthropy may play a catalytic role in pushing the hepatitis elimination agenda.
    • How to strengthen the role of civil society in promoting access and advocating for sound public health policy.
    • The role of national public health systems to eliminate hepatitis through financing, quality assurance, and increased access.
  • 13:30

    Strategic direction 5: innovation for acceleration

    Time: 13:30

    Golden Hall

    Innovation can help drive towards the overall objective of hepatitis elimination in a wide range of settings. This innovation session will highlight innovations related to hepatitis B and C products, programs and policies.

    Chairs: Dr. Joseph Tucker, University of North Carolina, USA and Dr. Francesco Marinucci, FIND

    Presentations:

    • Introduction.
    • Michael Ninburg, World Hepatitis Alliance
    • Decentralization of hepatitis services and the ECHO experience.
    • Dr. Henry Cohen, ECHO Project, Uruguay
    • Progress towards an HBV cure: A direct outcome of an integrated HIV / hepatitis research agenda in France.
    • Prof. Christian Trepo, Claude Bernard University, Lyon
    • Innovation panel.
    • − End Hep C SF: HCV Elimination by Prioritizing Engagement of Marginalized Populations
      − Identifying the optimal care model for HCV care in Cambodia, and overcoming barriers to decentralization and scale-up: Médecins Sans Frontières’ pilot program
      − Hepatitis Nurse Co-ordinator Treatment Monitoring Model’ for improved treatment outcomes at low cost in India
      − “Little HepB Hero” – the making of children hepatitis B ambassadors in families and community
      − Online-mediated HCV-RNA home-based testing to reduce incidence of hepatitis C virus infection among men who have sex with men in Amsterdam, The Netherlands – an initiative of the MC Free project
      − Innovative approaches towards a free village from viral hepatitis in Egypt

    Session objectives:

    • Learn the importance of innovation in developing hepatitis B and C control programs, policies and products.
    • Understand new products for hepatitis B and C control that could accelerate detection, treatment and retention.
    • Discuss new policies for expanding access to hepatitis B and C testing, treatment and prevention strategies.
    • Learn about new programs and public health interventions to optimize comprehensive hepatitis care.
  • 15:00

    Close of the World Hepatitis Summit 2017

    Time: 15:00

    Golden Hall

    Session Lead: Michael  Ninburg

    Closing thoughts from the 3 Partners of the World Hepatitis Summit 2017.

    Chairs: Michael Ninburg, World Hepatitis Alliance

    Presentations:

    • Event summary and closing thoughts from the chairs and partner organizations.
    • São Paulo declaration.
    • Community declaration.
    • Closing of the World Hepatitis Summit 2017.
  • 15:30

    Event close

    Time: 15:30